MYOM2 and cancer: Multiple myeloma (MM) is a common hematological malignancy, accounting for up to 10% ofhematological cancers and 1% of all cancers.1,2 It is characterized by aberrantclonal expansion of plasma cells within the bone marrow and the secretion of largeamounts of immunoglobulin, known as M protein.3 Increased use of new agents for the treatment of patients with MM has improvedsurvival.